DE112012005176B4 - Verfahren zum Synthetisieren von 1-(2-FluorbenzyI)-1H-pyrazolo[3,4-b]pyridin-3-formamidin-hydrochlorid - Google Patents
Verfahren zum Synthetisieren von 1-(2-FluorbenzyI)-1H-pyrazolo[3,4-b]pyridin-3-formamidin-hydrochlorid Download PDFInfo
- Publication number
- DE112012005176B4 DE112012005176B4 DE112012005176.9T DE112012005176T DE112012005176B4 DE 112012005176 B4 DE112012005176 B4 DE 112012005176B4 DE 112012005176 T DE112012005176 T DE 112012005176T DE 112012005176 B4 DE112012005176 B4 DE 112012005176B4
- Authority
- DE
- Germany
- Prior art keywords
- compound
- pyridine
- pyrazolo
- reaction
- fluorobenzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 13
- 230000002194 synthesizing effect Effects 0.000 title description 2
- MKJPBOVLAZADQJ-UHFFFAOYSA-N [amino(pyridin-3-yl)methylidene]azanium;chloride Chemical compound Cl.NC(=N)C1=CC=CN=C1 MKJPBOVLAZADQJ-UHFFFAOYSA-N 0.000 title 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 33
- 238000006243 chemical reaction Methods 0.000 claims abstract description 31
- 150000001875 compounds Chemical class 0.000 claims abstract description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 20
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims abstract description 15
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims abstract description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000019270 ammonium chloride Nutrition 0.000 claims abstract description 7
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 claims abstract description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims abstract description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- FFWQLZFIMNTUCZ-UHFFFAOYSA-N 1-(bromomethyl)-2-fluorobenzene Chemical compound FC1=CC=CC=C1CBr FFWQLZFIMNTUCZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000007810 chemical reaction solvent Substances 0.000 claims description 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical group CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical group COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 3
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 claims description 2
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 11
- DQASIYVADJWVLY-UHFFFAOYSA-N [1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridine-3-carboximidoyl]azanium;chloride Chemical compound Cl.C12=NC=CC=C2C(C(=N)N)=NN1CC1=CC=CC=C1F DQASIYVADJWVLY-UHFFFAOYSA-N 0.000 abstract description 9
- 230000015572 biosynthetic process Effects 0.000 abstract description 9
- 239000007858 starting material Substances 0.000 abstract description 9
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 abstract description 7
- TYXAGVKIICJXGF-UHFFFAOYSA-N 3-iodo-2h-pyrazolo[3,4-b]pyridine Chemical compound N1=CC=CC2=C(I)NN=C21 TYXAGVKIICJXGF-UHFFFAOYSA-N 0.000 abstract description 5
- 239000007789 gas Substances 0.000 abstract description 4
- WXXSNCNJFUAIDG-UHFFFAOYSA-N riociguat Chemical compound N1=C(N)C(N(C)C(=O)OC)=C(N)N=C1C(C1=CC=CN=C11)=NN1CC1=CC=CC=C1F WXXSNCNJFUAIDG-UHFFFAOYSA-N 0.000 abstract description 4
- 229960000529 riociguat Drugs 0.000 abstract description 4
- 239000011701 zinc Substances 0.000 abstract description 3
- 208000001435 Thromboembolism Diseases 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 239000002243 precursor Substances 0.000 abstract description 2
- AVPMRIWGOGRNBF-UHFFFAOYSA-N [bromo(fluoro)methyl]benzene Chemical compound FC(Br)C1=CC=CC=C1 AVPMRIWGOGRNBF-UHFFFAOYSA-N 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 239000007787 solid Substances 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 208000002815 pulmonary hypertension Diseases 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- LQCFFAGUCURQEC-UHFFFAOYSA-N 1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridine-3-carboximidamide Chemical compound C12=NC=CC=C2C(C(=N)N)=NN1CC1=CC=CC=C1F LQCFFAGUCURQEC-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000026151 Chronic thromboembolic pulmonary hypertension Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- RRLMPLDPCKRASL-ONEGZZNKSA-N (e)-3-(dimethylamino)prop-2-enal Chemical compound CN(C)\C=C\C=O RRLMPLDPCKRASL-ONEGZZNKSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- CSUUGTRFBZTTQW-UHFFFAOYSA-N 1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridine-3-carbonitrile Chemical compound FC1=CC=CC=C1CN1C2=NC=CC=C2C(C#N)=N1 CSUUGTRFBZTTQW-UHFFFAOYSA-N 0.000 description 1
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- QGHFTIKMLOOOSM-UHFFFAOYSA-N 5-fluoro-1-[(2-fluorophenyl)methyl]-3-iodopyrazolo[3,4-b]pyridine Chemical compound N1=C(I)C2=CC(F)=CN=C2N1CC1=CC=CC=C1F QGHFTIKMLOOOSM-UHFFFAOYSA-N 0.000 description 1
- GPEUANAWZCBBHU-UHFFFAOYSA-N 5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridine-3-carbonitrile Chemical compound N1=C(C#N)C2=CC(F)=CN=C2N1CC1=CC=CC=C1F GPEUANAWZCBBHU-UHFFFAOYSA-N 0.000 description 1
- CPPRYKBDKRBHIU-UHFFFAOYSA-N CC1(C(N)=NC(c2n[n](Cc(cccc3)c3F)c3ncccc23)=NC1N)N(C)C(OC)=O Chemical compound CC1(C(N)=NC(c2n[n](Cc(cccc3)c3F)c3ncccc23)=NC1N)N(C)C(OC)=O CPPRYKBDKRBHIU-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110414004.0 | 2011-12-12 | ||
| CN201110414004.0A CN102491974B (zh) | 2011-12-12 | 2011-12-12 | 1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法 |
| PCT/CN2012/085451 WO2013086935A1 (zh) | 2011-12-12 | 2012-11-28 | 1-（2-氟苄基）-1H -吡唑并[3，4- b]吡啶-3 -甲脒盐酸盐的合成方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE112012005176T5 DE112012005176T5 (de) | 2014-08-28 |
| DE112012005176B4 true DE112012005176B4 (de) | 2018-10-11 |
Family
ID=46183843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE112012005176.9T Active DE112012005176B4 (de) | 2011-12-12 | 2012-11-28 | Verfahren zum Synthetisieren von 1-(2-FluorbenzyI)-1H-pyrazolo[3,4-b]pyridin-3-formamidin-hydrochlorid |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8957210B2 (enExample) |
| JP (1) | JP5791825B2 (enExample) |
| CN (1) | CN102491974B (enExample) |
| DE (1) | DE112012005176B4 (enExample) |
| IL (1) | IL233066B (enExample) |
| IN (1) | IN2014DN05281A (enExample) |
| WO (1) | WO2013086935A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102491974B (zh) | 2011-12-12 | 2013-08-07 | 南京药石药物研发有限公司 | 1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法 |
| CN104086545A (zh) * | 2014-07-29 | 2014-10-08 | 安徽联创药物化学有限公司 | 1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-甲脒盐酸盐的合成方法 |
| CN105237531A (zh) * | 2015-10-15 | 2016-01-13 | 湖南华腾制药有限公司 | 一种利奥西呱中间体的制备方法及其中间体化合物 |
| WO2017106175A2 (en) | 2015-12-14 | 2017-06-22 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION |
| EP3554488A2 (en) | 2016-12-13 | 2019-10-23 | Cyclerion Therapeutics, Inc. | Use of sgc stimulators for the treatment of esophageal motility disorders |
| MX2021000363A (es) | 2018-07-11 | 2021-04-29 | Cyclerion Therapeutics Inc | Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales. |
| CN115947689B (zh) * | 2022-09-23 | 2025-08-29 | 湖南华腾制药有限公司 | 一种连续流微反应器合成利奥西呱中间体的方法 |
| CN117024334A (zh) * | 2023-07-20 | 2023-11-10 | 重庆医药高等专科学校 | 一种2-氟-3-羟基吡啶的合成方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020173514A1 (en) | 2000-11-22 | 2002-11-21 | Johannes-Peter Stasch | Pyridine-substituted pyrazolopyridine derivatives |
| WO2003095451A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Healthcare Ag | Carbamat-substituierte pyrazolopyridine |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009111279A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Pyrazole [3, 4-b] pyridine raf inhibitors |
| EP2352501B1 (en) | 2008-11-03 | 2014-01-01 | ChemoCentryx, Inc. | Compounds for use in the treatment of osteoporosis |
| CN101648909B (zh) * | 2009-09-14 | 2011-10-05 | 南京第一农药集团有限公司 | 一种氯代吡啶在无配体钯催化下制备氰基吡啶的方法 |
| US20110225969A1 (en) | 2010-03-19 | 2011-09-22 | Gm Global Technology Operations, Inc. | Compressor bypass to exhaust for particulate trap regeneration |
| ES2549979T3 (es) | 2010-05-26 | 2015-11-03 | Adverio Pharma Gmbh | El uso de estimuladores de la sGC, activadores de la sGC, solos y en combinaciones con inhibidores de la PDE5 para el tratamiento de esclerosis sistémica (EcS) |
| KR20140019004A (ko) * | 2010-05-27 | 2014-02-13 | 머크 샤프 앤드 돔 코포레이션 | 가용성 구아닐레이트 시클라제 활성화제 |
| GEP20166474B (en) | 2011-04-22 | 2016-05-10 | Pfizer | Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors |
| JP6054967B2 (ja) * | 2011-09-02 | 2016-12-27 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換アネレート化ピリミジンおよびその使用 |
| CN102491974B (zh) | 2011-12-12 | 2013-08-07 | 南京药石药物研发有限公司 | 1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法 |
-
2011
- 2011-12-12 CN CN201110414004.0A patent/CN102491974B/zh active Active
-
2012
- 2012-11-28 IN IN5281DEN2014 patent/IN2014DN05281A/en unknown
- 2012-11-28 US US14/364,040 patent/US8957210B2/en active Active
- 2012-11-28 DE DE112012005176.9T patent/DE112012005176B4/de active Active
- 2012-11-28 JP JP2014545075A patent/JP5791825B2/ja active Active
- 2012-11-28 WO PCT/CN2012/085451 patent/WO2013086935A1/zh not_active Ceased
-
2014
- 2014-06-10 IL IL233066A patent/IL233066B/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020173514A1 (en) | 2000-11-22 | 2002-11-21 | Johannes-Peter Stasch | Pyridine-substituted pyrazolopyridine derivatives |
| WO2003095451A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Healthcare Ag | Carbamat-substituierte pyrazolopyridine |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
Also Published As
| Publication number | Publication date |
|---|---|
| US8957210B2 (en) | 2015-02-17 |
| IN2014DN05281A (enExample) | 2015-04-03 |
| US20140309425A1 (en) | 2014-10-16 |
| CN102491974B (zh) | 2013-08-07 |
| JP2015500248A (ja) | 2015-01-05 |
| CN102491974A (zh) | 2012-06-13 |
| IL233066B (en) | 2019-01-31 |
| IL233066A0 (en) | 2014-07-31 |
| DE112012005176T5 (de) | 2014-08-28 |
| JP5791825B2 (ja) | 2015-10-07 |
| WO2013086935A1 (zh) | 2013-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE112012005176B4 (de) | Verfahren zum Synthetisieren von 1-(2-FluorbenzyI)-1H-pyrazolo[3,4-b]pyridin-3-formamidin-hydrochlorid | |
| WO2001017998A2 (de) | Verfahren zur herstellung substituierter pyrimidinderivate | |
| CN110028489B (zh) | 一种减压法制备苯甲酰胺类化合物的方法 | |
| DE202007018473U1 (de) | 9-Hydroxy-Risperidon (Paliperidon) | |
| CN104292089A (zh) | 一种1-氯-1’-氯乙酰基环丙烷的合成工艺 | |
| WO2012028645A1 (de) | VERFAHREN ZUR HERSTELLUNG VON 5-FLUOR-1H-PYRAZOLO[3,4-b]PYRIDIN-3-CARBONITRIL | |
| DE69027569T2 (de) | Verfahren zur Herstellung von Enynderivaten | |
| DE69615404T2 (de) | 2,7-SUBSTITUIERTE OCTAHYDROPYRROLO(1,2-a)PYRAZINDERIVATE | |
| DE69623117T2 (de) | Verfahren zur herstellung von 4-hydroxy-2-pyrrolidon | |
| CN106518865B (zh) | 一种1-烯基中氮茚衍生物的制备方法 | |
| WO1995018093A1 (de) | Verfahren zur herstellung von n-substituierten glycinsäuren oder glycinestern und verwendung des verfahrens zur indigosynthese | |
| EP1395586A2 (de) | Verfahren zur herstellung von zolpidem | |
| DE102005031348B4 (de) | Verfahren zur Herstellung von 3,4-Dichlorisothiazolcarbonsäure | |
| DE10332684B3 (de) | Verfahren zur Herstellung von Bifonazol | |
| DE4432610C1 (de) | Verfahren zur Herstellung von Selegilin-Hydrochlorid | |
| EP1124805A1 (de) | Verfahren zur herstellung von 4-[(2',5'-diamino-6'-halogenpyrimidin-4'-yl)amino]-cyclopent-2-enylmethanolen | |
| CN119751445B (zh) | 6-乙炔基吡唑并[1,5-a]吡啶的制备方法 | |
| EP0542086B1 (de) | Verfahren zur Herstellung von N-[(2-Chlor-pyridin-5-yl)methyl]-ethylendiamin | |
| CH605922A5 (en) | Quinazolines prepn. | |
| DE102004033313A1 (de) | Verfahren zur Herstellung von Enantiomeren 3-hydroxy-3-phenyl-propylaminen | |
| DE60308170T2 (de) | Verfahren zur herstellung von chinolinderivaten | |
| DE69914719T2 (de) | Verfahren zur Herstellung von 1-[(Cyclopent-3-en-1-yl)-methyl]-5-ethyl-6-(3,5-dimethylbenzoyl)-2,4-pyrimidindion | |
| DE69431706T2 (de) | Verfahren zur Herstellung von 5-Amino-dihydropyrrol, Zwischenprodukt davon und Verfahren zur Herstellung des Zwischenprodukts | |
| CN112480016A (zh) | 一种(e)-1-酰基-1-(3-喹喔啉酮)甲酮肟及其合成方法 | |
| EP3497089B1 (de) | Verfahren zur herstellung von 4-substituierten 2,3-dihydro-1-benzofuranderivaten durch zyklisierung von 2-(2-diazonium-6-substituierten-phenyl)ethanol salzen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R012 | Request for examination validly filed | ||
| R012 | Request for examination validly filed |
Effective date: 20140919 |
|
| R016 | Response to examination communication | ||
| R082 | Change of representative |
Representative=s name: SCHMITT-NILSON SCHRAUD WAIBEL WOHLFROM PATENTA, DE |
|
| R016 | Response to examination communication | ||
| R081 | Change of applicant/patentee |
Owner name: PHARMABLOCK SCIENCES (NANJING), INC., CN Free format text: FORMER OWNER: PHARMABLOCK (NANJING) R&D CO., LTD., JIANGSU, CN |
|
| R082 | Change of representative |
Representative=s name: SCHMITT-NILSON SCHRAUD WAIBEL WOHLFROM PATENTA, DE |
|
| R018 | Grant decision by examination section/examining division | ||
| R020 | Patent grant now final |